Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tracking blood markers over time may reveal hidden heart risk

NCT ID NCT07817576

Knowledge-focused Sponsor: University Hospital Freiburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers at University Hospital Freiburg are studying how blood levels of hsCRP and Lp(a), two markers linked to heart disease, change over time in patients who have had these tests more than once. The study asks whether a high result on a first test often returns to normal later, and whether patients whose levels stay high across repeated tests face a higher risk of death than those whose high level was temporary. The study uses existing medical records and death registry data from about 110,000 participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If repeated testing proves more informative, doctors could use serial biomarker patterns to spot patients at higher risk and tailor monitoring or treatment.
What could go wrong
This observational study cannot prove that biomarker changes cause worse outcomes, and results may not apply to people who have not had these tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

110,000 people

The number who actually took part.

Started

Jan 2004

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Agnostic design. All-comers cohort at the University Hospital Freiburg, Department of Cardiology. Locations Freiburg and Bad-Krozingen

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Available Biomarker Measurement Exclusion Criteria: \- \< 18 years, Biomarker not available

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCVD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease cardiovascular disorder chronic kidney disease heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCVD CKD Heart failure

Contacts and locations

Locations

  • Department of Cardiology - Freiburg - Bad Krozingen

    Freiburg im Breisgau, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.